Human immunodeficiency virus 1

1 INDICATIONS AND USAGE Abacavir, lamivudine and zidovudine tablet, a combination of abacavir, lamivudine, and zidovudine, each nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.( 1 ) Abacavir, lamivudine and zidovudine tablet is indicated in combination with other antiretrovirals or alone for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id e180b9ff-1e7c-422a-9fe7-afd39eee3e4e · verified 2026-10-30

1 INDICATIONS AND USAGE Abacavir and lamivudine tablet, a combination of abacavir and lamivudine, both nucleoside analogue HIV-1 reverse transcriptase inhibitors, is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 61b0304c-2258-40ed-9fc8-bc363b0906f6 · verified 2026-10-30

1 INDICATIONS AND USAGE TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 4018a8c7-db0d-481e-b50a-a469ba32ec4b · verified 2026-10-30

1 INDICATIONS AND USAGE BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id a3c4a0eb-71e8-4b35-9706-240874b78ee0 · verified 2026-10-30

INDICATIONS AND USAGE SYMTUZA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id a8468da1-a6e7-4a14-a108-23915ccaeee8 · verified 2026-10-30

1 INDICATIONS AND USAGE DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 9b88da25-ebce-49ae-8c8a-dcee6f465957 · verified 2026-10-30

1 INDICATIONS AND USAGE PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history;

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 213c6c93-b2a7-43c1-a380-c3799a9343b0 · verified 2026-10-30

1 INDICATIONS AND USAGE IDVYNSO™ is indicated as a complete two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine [see Microbiology (12.4) and Clinical Studies (14) ].

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 36245cd8-5e98-408c-a2df-38f9642b0827 · verified 2026-10-30

1 INDICATIONS AND USAGE DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] .

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 246882d6-9ed0-452a-8da7-aa919a22b571 · verified 2026-10-30

1 INDICATIONS & USAGE Efavirenz in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id f1a4251a-e04d-48aa-ae58-44b30df1de0d · verified 2026-10-30

1 INDICATIONS AND USAGE Efavirenz, emtricitabine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id e45a9953-97a0-4885-acbd-5af0f22c4f74 · verified 2026-10-30

1 INDICATIONS AND USAGE Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 27623aed-629d-4406-a0bf-4f234fc4e6c6 · verified 2026-10-30

1 INDICATIONS AND USAGE GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA [see Clinical Studies (14) ].

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]; SPL id 7bb9d232-d878-47d0-8262-abc4d06b37f7 · verified 2026-10-30

1 INDICATIONS AND USAGE STRIBILD ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older weighing at least 35 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of STRIBILD [see Clinical Studies (14) ] .

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor [EPC]; SPL id 65c2d2eb-d180-41c3-b346-9cdc6e52d5ed · verified 2026-10-30

1 INDICATIONS AND USAGE HIV-1 Treatment ( 1.1 ) Emtricitabine and tenofovir disoproxil fumarate tablet is a two-drug combination of emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, and is indicated: • in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 1289b02c-50f7-4adc-80d1-24afc1bad01b · verified 2026-10-30

1 INDICATIONS AND USAGE Emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: • as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy or • to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no treatment failure and no known subst

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 7193c90e-456c-4cfb-8181-65a1618dae51 · verified 2026-10-30

1 INDICATIONS AND USAGE ODEFSEY is indicated as a complete regimen for the treatment of HIV-1 infection in adult and pediatric patients weighing at least 25 kg: as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of ODEFSEY [see Microbiology (12.4) and Clinical S

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 130b8bbc-f660-40ff-831c-139734f90b99 · verified 2026-10-30

1 INDICATIONS AND USAGE COMPLERA ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy or to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no treatment failure and no known substitutions associated with resistance to the individual component

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 21d7850d-11ea-43cc-84a5-0dae02a19ce6 · verified 2026-10-30

1 INDICATIONS AND USAGE Emtricitabine, rilpivirine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: • as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy or • to replace a stable antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no treatment failure and no known subst

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id d9a4185e-43fa-4aeb-9b0f-8db01b166038 · verified 2026-10-30

1.1 Treatment of HIV-1 Infection Emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg [see CLINICAL STUDIES (14)].

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 2c4cdf7a-45da-784b-e063-6294a90a82b9 · verified 2026-10-30

1 INDICATIONS AND USAGE Etravirine, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients and pediatric patients 2 years of age and older [see Microbiology (12.4) and Clinical Studies (14) ] Etravirine is a human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for treatment of HIV-1 infection in treatment-experienced patients 2 years of age and older.

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 4b21f36b-78b4-41db-ae59-814076cf5b90 · verified 2026-10-30

1 INDICATIONS AND USAGE TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.

Human Immunodeficiency Virus 1 Post-attachment Fusion Inhibitor [EPC]; SPL id c04624be-0e28-4902-954c-730ccdbfd162 · verified 2026-10-30

1 INDICATIONS & USAGE Lamivudine and zidovudine tablets a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id aa348cf2-2e1b-486f-9bec-5ccf67879175 · verified 2026-10-30

1 INDICATIONS AND USAGE Lamivudine oral solution, USP is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id 476c3997-b596-17d2-e063-6394a90a6ca1 · verified 2026-10-30

1 INDICATIONS & USAGE Nevirapine extended-release tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 6 years of age or older with a body surface area (BSA) of 1.17 m 2 or greater [see Clinical Studies ( 14.1 , 14.2 )].

Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]; SPL id de3914b8-5c5c-4b11-a9f9-39f592d51c1d · verified 2026-10-30